Markets

AbbVie Enters Multi-Year Collaboration With Iambic To Accelerate Discovery And Development Of Small Molecule Therapies Across Immunology, Neuroscience And Oncology; Iambic To Receive Upfront Payment And Is Eligible For Milestone Payments And Tiered Royalties

Sep 21, 2026 · 08:06 AM ET· updated 1h ago

The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates."We are excited about the purpose-built AI capabilities Iambic is bringing to

Why It Matters

AbbVie is paying Iambic to use AI technology to find new medicines faster. This shows AbbVie thinks AI tools could help them discover better drugs.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABBV265.28

+1.32 (+0.50%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.